WASHINGTON--(BUSINESS WIRE)--Reflecting its commitment to patient safety and ongoing medical research, Medtronic, Inc. (NYSE:MDT), today announced the findings from two clinical trials highlighting the ability of next-generation technologies to improve patient outcomes following interventional procedures. Results of the AMEthyst and EXPORT trials were presented this week at the 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
